IOL CHEMICALS AND PHARMACEUTICALS LIMITED

Financials IOL Chemicals and Pharmaceuticals Limited

Equities

IOLCP

INE485C01011

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:46 14/05/2024 pm IST			5-day change	1st Jan Change
376.6 ^INR	+0.82%		-2.59%	-18.69%

19/03	IOL Chemicals Gets Zero Observations from Brazilian Health Regulatory Agency After Inspection of Units	MT
19/02	IOL Chemicals Gets Nod to Export Diabetes Drug to China	MT

Valuation

Fiscal Period: March	2023	2024	2025	2026
Capitalization ¹	16,608	22,111	-	-
Enterprise Value (EV) ¹	16,608	22,111	22,111	22,111
P/E ratio	11.9 x	11.9 x	9.49 x	8.87 x
Yield	1.41%	1.69%	1.89%	2.04%
Capitalization / Revenue	0.75 x	0.92 x	0.83 x	0.78 x
EV / Revenue	0.75 x	0.92 x	0.83 x	0.78 x
EV / EBITDA	7.36 x	7.35 x	5.91 x	5.5 x
EV / FCF	-18.5 x	13.7 x	260 x	22.7 x
FCF Yield	-5.39%	7.28%	0.38%	4.4%
Price to Book	1.1 x	1.34 x	1.2 x	1.08 x
Nbr of stocks (in thousands)	58,706	58,706	-	-
Reference price ²	282.9	376.6	376.6	376.6
Announcement Date	28/04/23	-	-	-

¹INR in Million²INR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März	2023	2024	2025	2026
Net sales ¹	22,171	23,960	26,650	28,405
EBITDA ¹	2,257	3,010	3,743	4,020
EBIT ¹	2,051	2,540	3,164	3,380
Operating Margin	9.25%	10.6%	11.87%	11.9%
Earnings before Tax (EBT) ¹	1,886	2,529	3,152	3,367
Net income ¹	1,391	1,857	2,331	2,490
Net margin	6.28%	7.75%	8.75%	8.77%
EPS ²	23.70	31.60	39.70	42.45
Free Cash Flow ¹	-895.5	1,610	85	973
FCF margin	-4.04%	6.72%	0.32%	3.43%
FCF Conversion (EBITDA)	-	53.49%	2.27%	24.2%
FCF Conversion (Net income)	-	86.7%	3.65%	39.07%
Dividend per Share ²	4.000	6.350	7.100	7.700
Announcement Date	28/04/23	-	-	-

¹INR in Million²INR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4
Net sales ¹	5,414	5,235	5,872	5,632	5,982	6,002	6,319
EBITDA ¹	-	426.9	953	725.2	849.5	770	778
EBIT	-	-	-	-	-	-	-
Operating Margin	-	-	-	-	-	-	-
Earnings before Tax (EBT)	-	-	-	-	-	-	-
Net income ¹	-	237.9	647.8	458.6	547	484	494
Net margin	-	4.54%	11.03%	8.14%	9.14%	8.06%	7.82%
EPS	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-
Announcement Date	14/11/22	07/02/23	28/04/23	09/08/23	-	-	-

¹INR in Million

Estimates

Balance Sheet Analysis

Fiscal Period: March	2023	2024	2025	2026
Net Debt	-	-	-	-
Net Cash position	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-
Free Cash Flow ¹	-896	1,610	85	973
ROE (net income / shareholders' equity)	9.6%	11.8%	13.3%	12.8%
ROA (Net income/ Total Assets)	-	-	-	-
Assets ¹	-	-	-	-
Book Value Per Share ²	257.0	282.0	315.0	349.0
Cash Flow per Share	-	-	-	-
Capex ¹	2,118	2,000	1,975	1,975
Capex / Sales	9.55%	8.35%	7.41%	6.95%
Announcement Date	28/04/23	-	-	-

¹INR in Million²INR

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for IOL Chemicals and Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

376.6 INR

Average target price

517 INR

Spread / Average Target

+37.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IOL CHEMICALS AND PHARMACEUTICALS LIMITED	-18.69%	263M
ELI LILLY AND COMPANY	+29.99%	682B
NOVO NORDISK A/S	+30.35%	586B
JOHNSON & JOHNSON	-3.75%	364B
MERCK & CO., INC.	+17.82%	327B
ABBVIE INC.	+3.28%	285B
ASTRAZENECA PLC	+15.53%	240B
NOVARTIS AG	+10.16%	209B
ROCHE HOLDING AG	-8.14%	203B
AMGEN INC.	+7.41%	165B

Other Pharmaceuticals